Endocrinology Advisor3d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
News-Medical.Net on MSN2d
US FDA approves first treatment for hyperphagia in Prader-Willi syndrome
The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
"My daughter struggles with the same rare condition as Katie Price’s son - this is what life is like for us"
A new drug could change everything for children like seven-year-old Liliana, who has Prader-Willi syndrome, a rare genetic ...
Pharmabiz6d
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome
The FDA’s approval of Vykat XR represents a monumental step forward in addressing the longstanding unmet needs of individuals living with PWS and their families,” said Stacy Ward, chief executive ...
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...
The Manila Times4d
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is ...
Soleno Therapeutics price target raised to $100 from $70 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...